IL114865A - Morpholine derivatives pharmaceutical compositions containing them and their use - Google Patents
Morpholine derivatives pharmaceutical compositions containing them and their useInfo
- Publication number
- IL114865A IL114865A IL11486595A IL11486595A IL114865A IL 114865 A IL114865 A IL 114865A IL 11486595 A IL11486595 A IL 11486595A IL 11486595 A IL11486595 A IL 11486595A IL 114865 A IL114865 A IL 114865A
- Authority
- IL
- Israel
- Prior art keywords
- 4alkyl
- pct
- hydrogen
- 4alkoxy
- hydroxy
- Prior art date
Links
- 150000002780 morpholines Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006413 ring segment Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9416427A GB9416427D0 (en) | 1994-08-15 | 1994-08-15 | Therapeutic agents |
| GBGB9509605.3A GB9509605D0 (en) | 1995-05-11 | 1995-05-11 | Therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL114865A0 IL114865A0 (en) | 1995-12-08 |
| IL114865A true IL114865A (en) | 1999-06-20 |
Family
ID=26305450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11486595A IL114865A (en) | 1994-08-15 | 1995-08-08 | Morpholine derivatives pharmaceutical compositions containing them and their use |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5824678A (el) |
| EP (1) | EP0777659B1 (el) |
| JP (1) | JP2002502351A (el) |
| AT (1) | ATE201866T1 (el) |
| AU (1) | AU691327B2 (el) |
| CA (1) | CA2195972A1 (el) |
| DE (1) | DE69521208T2 (el) |
| DK (1) | DK0777659T3 (el) |
| ES (1) | ES2157337T3 (el) |
| GR (1) | GR3036006T3 (el) |
| IL (1) | IL114865A (el) |
| PT (1) | PT777659E (el) |
| WO (1) | WO1996005181A1 (el) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| ATE285776T1 (de) * | 1996-12-02 | 2005-01-15 | Merck Sharp & Dohme | Verfahren und vorrichtung zur kompensation von durch chrominanzsignalverarbeitung verursachten luminanzstörungen |
| CA2273853A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating cognitive disorders |
| ES2227728T3 (es) * | 1996-12-02 | 2005-04-01 | MERCK SHARP & DOHME LTD. | Uso de antagonistas del receptor de nk-1 para tratar trastornos de ests. |
| WO1998024441A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating major depressive disorders with anxiety |
| US6613765B1 (en) | 1996-12-02 | 2003-09-02 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating major depressive disorders |
| US6114315A (en) * | 1996-12-02 | 2000-09-05 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety |
| JP2001504848A (ja) * | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | 重症不安障害の治療のためのｎｋ−１受容体拮抗薬の使用 |
| US5977104A (en) * | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
| ATE282416T1 (de) * | 1996-12-02 | 2004-12-15 | Merck Sharp & Dohme | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen |
| AU731672B2 (en) * | 1996-12-02 | 2001-04-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating bipolar disorders |
| US6100256A (en) * | 1996-12-02 | 2000-08-08 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptors antagonists for treating schizophrenic disorders |
| AU734872B2 (en) * | 1996-12-02 | 2001-06-21 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating movement disorders |
| AU732633B2 (en) * | 1996-12-02 | 2001-04-26 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating schizophrenic disorders |
| JP2001504851A (ja) * | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用 |
| WO1998047513A1 (en) * | 1997-04-24 | 1998-10-29 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating eating disorders |
| GB9716457D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
| AU738047B2 (en) * | 1997-08-04 | 2001-09-06 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating mania |
| GB9716463D0 (en) * | 1997-08-04 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic agents |
| WO1999007375A1 (en) * | 1997-08-04 | 1999-02-18 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating aggressive behaviour disorders |
| US6087348A (en) * | 1997-12-01 | 2000-07-11 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating stress disorders |
| US6156749A (en) * | 1997-12-01 | 2000-12-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating movement disorders |
| US6271230B1 (en) | 1997-12-01 | 2001-08-07 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating cognitive disorders |
| WO2000026214A1 (en) * | 1998-10-30 | 2000-05-11 | Merck & Co., Inc. | Linear process for the preparation of a morpholine compound |
| GB9907571D0 (en) * | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Compounds |
| US7279547B2 (en) * | 2000-02-10 | 2007-10-09 | University Of Connecticut | Insecticidal compounds and methods for selection thereof |
| AU2001249144A1 (en) | 2000-03-13 | 2001-09-24 | Ortho-Mcneil Pharmaceutical, Inc. | Novel cyclopentene derivatives useful as antagonists of the motilin receptor |
| US6423714B2 (en) | 2000-03-13 | 2002-07-23 | Ortho Mcneil-Pharmaceutical, Inc.. | Cyclohexene derivatives useful as antagonists of the motilin receptor |
| US6384031B2 (en) | 2000-03-13 | 2002-05-07 | Ortho-Mcneil Pharmaceutical, Inc. | Cyclobutene derivatives useful as antagonists of the motilin receptor |
| WO2003101459A1 (en) * | 2002-05-29 | 2003-12-11 | The Regents Of The University Of California | Antagonizing nk1 receptors inhibits consumption of substances of abuse |
| RU2388751C2 (ru) | 2004-07-15 | 2010-05-10 | Амр Текнолоджи, Инк. | Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
| WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
| KR101589551B1 (ko) | 2005-07-15 | 2016-02-02 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| AU2007300627B2 (en) | 2006-09-22 | 2012-02-16 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| CL2008000046A1 (es) | 2007-01-10 | 2008-05-09 | Angeletti P Ist Richerche Bio | Compuestos derivados de 2-(4-piperidin-3-il-fenil)-7-amido-2,7a-dihidro-1h-indazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir el cancer, enfermedades inflamatorias, lesiones por reperfusion, afeccione |
| BRPI0807972A2 (pt) | 2007-01-24 | 2014-06-10 | Glaxo Group Ltd | Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1 |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体 |
| CA2717509A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| SG175420A1 (en) | 2009-05-12 | 2011-12-29 | Albany Molecular Res Inc | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof |
| ES2528404T3 (es) | 2009-05-12 | 2015-02-10 | Bristol-Myers Squibb Company | Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos |
| MX2011011901A (es) | 2009-05-12 | 2012-01-20 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas. |
| AU2010307198C9 (en) | 2009-10-14 | 2014-02-13 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| SI2606134T1 (sl) | 2010-08-17 | 2019-08-30 | Sirna Therapeutics, Inc. | RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA) |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
| EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| RU2660429C2 (ru) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Новые соединения, которые являются ингибиторами erk |
| EP2925888B1 (en) | 2012-11-28 | 2017-10-25 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| US8846657B2 (en) | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| EP3706747A4 (en) | 2017-11-08 | 2021-08-04 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| CN111004190A (zh) * | 2019-11-08 | 2020-04-14 | 广州曼翔医药有限公司 | 一种阿瑞匹坦中间体的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0600952B1 (en) * | 1991-08-20 | 1996-04-17 | MERCK SHARP & DOHME LTD. | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
| IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| WO1995018124A1 (en) * | 1993-12-29 | 1995-07-06 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
-
1995
- 1995-08-07 AT AT95927862T patent/ATE201866T1/de not_active IP Right Cessation
- 1995-08-07 ES ES95927862T patent/ES2157337T3/es not_active Expired - Lifetime
- 1995-08-07 PT PT95927862T patent/PT777659E/pt unknown
- 1995-08-07 AU AU31855/95A patent/AU691327B2/en not_active Ceased
- 1995-08-07 CA CA002195972A patent/CA2195972A1/en not_active Abandoned
- 1995-08-07 WO PCT/GB1995/001868 patent/WO1996005181A1/en active IP Right Grant
- 1995-08-07 US US08/793,186 patent/US5824678A/en not_active Expired - Fee Related
- 1995-08-07 DK DK95927862T patent/DK0777659T3/da active
- 1995-08-07 JP JP50710696A patent/JP2002502351A/ja not_active Withdrawn
- 1995-08-07 DE DE69521208T patent/DE69521208T2/de not_active Expired - Fee Related
- 1995-08-07 EP EP95927862A patent/EP0777659B1/en not_active Expired - Lifetime
- 1995-08-08 IL IL11486595A patent/IL114865A/xx active IP Right Grant
-
2001
- 2001-06-07 GR GR20010400305T patent/GR3036006T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69521208D1 (de) | 2001-07-12 |
| AU3185595A (en) | 1996-03-07 |
| AU691327B2 (en) | 1998-05-14 |
| EP0777659B1 (en) | 2001-06-06 |
| ATE201866T1 (de) | 2001-06-15 |
| JP2002502351A (ja) | 2002-01-22 |
| EP0777659A1 (en) | 1997-06-11 |
| WO1996005181A1 (en) | 1996-02-22 |
| ES2157337T3 (es) | 2001-08-16 |
| IL114865A0 (en) | 1995-12-08 |
| DE69521208T2 (de) | 2001-11-08 |
| GR3036006T3 (en) | 2001-09-28 |
| CA2195972A1 (en) | 1996-02-22 |
| DK0777659T3 (da) | 2001-09-03 |
| PT777659E (pt) | 2001-09-28 |
| US5824678A (en) | 1998-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL114865A (en) | Morpholine derivatives pharmaceutical compositions containing them and their use | |
| ES2128791T3 (es) | Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos. | |
| IL176110A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| PL328310A1 (en) | Derivatives of quinazoline | |
| ES2159558T3 (es) | Derivados de guanidina como inhibidores del intercambio na+/h+ en las celulas. | |
| IL176107A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
| ATE161843T1 (de) | Chinuclidine derivate als squalen synthase inhibitoren | |
| ES2098947T3 (es) | Derivados de beta,beta-dimetil-4-piperidinoetanamina como inhibidores de la biosintesis del colesterol. | |
| IL124966A0 (en) | 1-indanyl- and 1-indanylidene-acetic derivatives | |
| JO2231B1 (en) | Derivatives of Trahydroperan and its use as a therapeutic agent | |
| AP9901559A0 (en) | Tricyclic 3-keto derivatives of 6-0-methylerythromycin. | |
| PA8471901A1 (es) | Derivados de 2"-desoxi higromicina | |
| ECSP993239A (es) | Derivados de higromicina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |